Update
$BriaCell Therapeutics (BCTX.US)$ BriaCell Reports Outperforming Metastatic Breast Cancer Patients and Standard-Beating Survival Data
3 MINUTES AGO, 7:50 AM EDT
VIA GLOBENEWSWIRE
55% of BriaCell patients1 remained alive one year since enrollment in BriaCell's Phase 2 study, markedly exceeding the survival rate of current standard of care for similar patients
Multiple outperforming patients with overall survival of over 2 years
Survival benefit observed even in heavily pre-treated patients who failed treatment with checkpoint inhibitors (CPIs) and/or antibody-drug conjugates (ADCs)
Final median overall survival calculation for the Phase 2 study is pending, as many patients remain alive
No Bria-IMT™ related discontinuations reported to date
3 MINUTES AGO, 7:50 AM EDT
VIA GLOBENEWSWIRE
55% of BriaCell patients1 remained alive one year since enrollment in BriaCell's Phase 2 study, markedly exceeding the survival rate of current standard of care for similar patients
Multiple outperforming patients with overall survival of over 2 years
Survival benefit observed even in heavily pre-treated patients who failed treatment with checkpoint inhibitors (CPIs) and/or antibody-drug conjugates (ADCs)
Final median overall survival calculation for the Phase 2 study is pending, as many patients remain alive
No Bria-IMT™ related discontinuations reported to date
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
